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Lymphoma is a malignant transformation of the 
lymph nodes and lymphoid tissue. Tuberculosis is an 
infection caused by Mycobacterium tuberculosis [1]. 
Lymphoma is the sixth most common cancer in Indonesia 
[2]. Tuberculosis infection is endemic in developing 
countries with a high mortality rate. In Indonesia, the 
prevalence of tuberculosis is 759 out of 100,000 
population with the age of > 15 years [3]. We report 
a case of clinical suspicion of having lymphoma recurrent 
disease with false-positive Positron Emission Tomography/
Computed Tomography Fluorodeoxyglucose (F-18 FDG 
PET) and final tuberculosis infection confirmed by 
histopathology finding. 
Lymphoma and tuberculosis might present similar 
clinical features although both are different disease 
entities. Lymphoma has a relatively worse prognosis 
compared to tuberculosis; hence, early disease 
differentiation is important to commence precise 
treatment [1]. 
Lymphadenopathy, fever, weight loss, malaise, and 
respiratory symptoms are clinical features that could 
be shared in lymphoma and tuberculosis [1,4,5]. 
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A B S T R A C T
Introduction: Lymphoma and tuberculosis in several cases share similar clinical features that are 
difficult to differentiate. Lymphadenopathy, fever, malaise, weight loss, and respiratory 
symptoms are clinical features that could be found in both lymphoma and tuberculosis. Positron 
Emission Tomography/Computed Tomography Fluorodeoxyglucose (F-18 FDG PET) is a pivotal 
modality for imaging patients with cancer. Several non-malignant diseases like tuberculosis 
infection show high FDG uptake and lead to low specificity of F-18 FDG PET.
Case Presentation: This case report describes a 55-year-old male patient with a history of Diffuse 
Large B-cell Lymphoma (DLBCL) who was suspected of having a recurrent disease. The patient 
has had a 6-month remission period after 6 cycles of R-CHOP regimen chemotherapy. He denied 
any known history of tuberculosis infection and HIV. F-18 FDG PET was performed to assess the 
extent of suspected lymphoma recurrent disease. F-18 FDG PET demonstrated multiple 
hypermetabolic bilateral neck region, mediastinum, and bilateral axilla lymphadenopathies. 
There were also multiple high FDG uptakes in the liver, mesocolon, and bones. The patient was 
suspected of having a lymphoma recurrent disease based on these findings. He underwent an 
excisional biopsy in the neck and was found to have lymphadenitis granulomatous disease from 
tuberculosis. Based on the histopathology finding, the patient received anti-tuberculosis drugs 
for 12 months and showed relief of signs and symptoms. F-18 FDG PET for anti-tuberculosis 
treatment evaluation revealed a complete metabolic response.
Conclusion: Tuberculosis should be one of the differential diagnoses when a lymphoma recurrent 
disease is suspected. Clinical features, laboratory results, and imaging findings sometimes show 
similarities between lymphoma and tuberculosis. Histopathology evaluation is mandatory to 
confirm the diagnosis. 
CASE REPORT
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Figure 1. (A, B, C, D) F-18 FDG PET suggestive for lymphoma 
recurrent (before anti-tuberculosis treatment)
Figure 2. Histopathological examination of neck lymphadenopathy 
showed caseous necrotic area (*) and Langhans datia cells (black 
arrow)
Figure 3. F-18 FDG PET after anti-tuberculosis treatment suggestive 
for complete metabolic response
Tuberculosis is diagnosed with histopathology 
examination or bacterial culture. Imaging procedures 
are routinely performed for post-treatment evaluation 
in lymphoma and tuberculosis. F-18 FDG PET is a pivotal 
modality for imaging patients with cancer. However, 
F-18 FDG PET has low specificity in several non-malignant 
diseases like tuberculosis as the infection might show 
high FDG uptake [6,7]. 
CASE PRESENTATION
A 55-year-old male patient was admitted to our 
center with multiple lymphadenopathies and a spleen 
mass found from the contrast-enhanced abdominal 
computed tomography (CT) scan. The patient denied 
any history of either tuberculosis infection or HIV. 
Surgery was performed to excise the spleen mass, and 
the diagnosis of diffuse large B-cell lymphoma (DLBCL) 
was made from the histopathology finding. Baseline 
pre-chemotherapy F-18 FDG PET demonstrated stage 
IV lymphoma involving lymph nodes (above and under 
diaphragm) and bone marrow. The patient received 6 
cycles of high-dose R-CHOP chemotherapy regimens and 
showed remission for 6 months afterward. He 
subsequently complained of having a new mass in the 
neck, weight loss of ten kilograms in two months, and 
fever (more than 38°C). Another F-18 FDG PET was 
performed for restaging suspected recurrent lymphoma 
and found multiple new hypermetabolic 
lymphadenopathies in the neck, mediastinum, and 
bilateral axilla (not seen in the initial F-18 FDG PET). 
F-18 FDG PET also found hypermetabolic lesions in the 
liver, mesocolon, and bones (Figure 1). The patient 
underwent an excisional biopsy in the neck mass which 
was confirmed to be lymphadenitis granulomatous 
disease from tuberculosis (Figure 2). He received anti-
tuberculosis drugs for 1 year and showed good response, 
clinical health improvement, and neck mass regression. 
This response was confirmed by post-anti-tuberculosis 
therapy F-18 FDG PET showing a complete metabolic 
response (Figure 3). 
F-18 FDG PET acquisition was performed using a 
PET camera (Gemini, Phillips Healthcare, US). A Dose 
of 0.10 mCi/kgBW FDG was intravenously administered 
to the patient after 6-hour fasting with a blood 
glucose level of less than 150 mg/dl. FDG was 
administered 45-90 minutes before the acquisition. 
Low-dose CT was applied with a slice thickness of 
10 mm. The three-dimensional acquisition was done 
for 180 sec per bed position followed by a 
reconstruction model with the 3D-ordered-subsets 
expectation maximization method.
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glucose-transporter (GLUT) protein. Lymphadenopathy 
in tuberculosis and lymphoma shows high FDG uptake. 
The maximum standard uptake value (SUV max) could 
not accurately differentiate between tuberculosis and 
lymphoma lymphadenopathy. 
Table 1. Comparison between F-18 FDG PET and MRI for 





Higher sensitivity for 
le sion detection 
helps detect splenic 
T-cell lymphoma
Low specificity; 
inflammation is also 
detected; gastric MALT 
lymphoma and cerebral 
lymphoma are not 
detected*
MRI Higher sensitivity for 
lesion detection can 
help detect more 
subcutaneous lesion
Normal lymph nodes 
are also detected, 
mediastinum lesions 
are not detected**
CT scan First-line diagnostic 
imaging of systemic 
disease
Less accurate for the 
initial staging and 
evaluation of treatment 
response 
Note. MALT: Mucosa Associated Lymphoid Tissue
*Owing to physiologic gastric and brain cortical accumulation of FDG 
**Owing to the artifact caused by cardiovascular motion
Some studies have reported several methods in 
differentiating infection and malignancy based on F-18 
FDG PET acquisition protocols, characteristics, and 
parameters. At first, a threshold of SUV max value is 
proposed to distinguish between infection and 
malignancy. Another method is using dual-time F-18 
FDG PET imaging acquisition protocol, based on varying 
levels of glucose-6-phosphatase activities among 
different tumor cell types, inflammatory, and normal 
cells. The most recent method is using the influx rate 
constant (Ki) which is reported to be closely related 
to neutrophil activation. However, these methods are 
not well validated as several other factors could also 
influence FDG uptake and are not applicable in daily 
clinical practice [13]. Good knowledge of specific 
malignant disease patterns and correlation with other 
modalities such as tumor marker and anatomical 
imaging is important for F-18 FDG PET interpretation 
in the clinical setting. It is also important to always 
consider some tumor markers and other clinical 
assessment pitfalls commonly used in diagnosing 
malignancy. New specific radiopharmaceutical for 
tuberculosis such as Tc-99m Ethambutol might also 
be helpful in this setting [14].
DISCUSSION
Our case report depicts a tuberculosis patient with 
a history of lymphoma showing clinical features and 
F-18 FDG PET findings of lymphoma recurrent disease. 
Misdiagnosis could increase morbidity and mortality 
rates. Accurate tuberculosis diagnosis can be obtained 
by histopathology examination or bacterial culture. 
Tuberculosis is a “great imitator” that can mimic 
other several diseases including malignant lymphoma. 
Tuberculosis usually affects the lungs; however, it 
can also involve extrapulmonary organs such as the 
lymph node. The lymph node is one of the 
extrapulmonary organs that are most commonly 
infected by tuberculosis. It is difficult for clinicians 
to non-invasively differentiate lymphadenopathy due 
to lymphoma or tuberculosis [1].
Tuberculosis rapidly grows and develops in patients 
with an impaired immune system or an immune-
compromised state. This might be due to the immune 
suppression related to lymphoma malignancy or post-
chemotherapy adverse effects in addition to living in 
an endemic region of tuberculosis. Tuberculosis is usually 
found in immunocompromised individuals, such as HIV 
and cancer patients. The immune suppression, in this 
case, might be related to lymphoma malignancy and 
post-chemotherapy adverse effects. Chemotherapy is 
the treatment of choice for lymphoma with the adverse 
effect of immune suppression. The compromised 
immune system enables Mycobacterium tuberculosis to 
easily infect patients, especially those living in the 
endemic region [8,9].
Diagnostic imaging has important roles in diagnoses 
and treatment evaluation for both tuberculosis and 
lymphoma cases (Table 1). Chest X-Ray is routinely 
performed for patients having suspected lung 
tuberculosis. Meanwhile, CT, magnetic resonance 
imaging (MRI), or PET could evaluate both pulmonary 
and extrapulmonary tuberculosis. CT is preferred for 
evaluating tuberculosis in the chest, gastrointestinal, 
and urogenital systems. MRI is preferred for evaluating 
tuberculosis in the central nervous system [10]. F-18 
FDG PET has been widely used for staging and 
treatment response evaluation in lymphoma. F-18 FDG 
PET detects relapse disease earlier than anatomical 
imaging such as CT or MRI [11]. F-18 FDG PET could 
differentiate indolent and aggressive lymphoma. F-18 
FDG PET demonstrates lower FDG uptake in indolent 
than in aggressive lymphoma [12].
One of F-18 FDG PET limitations is low specificity. 
FDG is accumulated not only in tumor cells but also in 
macrophage cells, granulation tissue, or inflammation 
tissue. FDG avidity represents the glucose metabolism 
level of the tumor cell and inflammation process. FDG 
is a glucose analog that is transported inside cells via 
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CONCLUSIONS
Tuberculosis and lymphoma are two different disease 
entities with similar clinical features and diagnostic 
imaging findings. It makes a differentiation between 
the two entities difficult. Tuberculosis is a “Great 
Imitator” for several other diseases including malignant 
lymphoma. Tuberculosis infection should be considered 
as a differential diagnosis when interpreting F-18 FDG 
PET in a patient with a history of lymphoma who had 
received chemotherapy and live in a developing country.
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